Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | THRB | P10828 | 4/20 | 0.38 |
| ▸ | THRA | P10827 | 3/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.32 |
| ▸ | KLK1 | P06870 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.30 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.30 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.30 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10192340 | 1.00 | ALDH1A1 (0.44) | ALDH1A1TSHRTHRBTHRACYP3A4 | |
| SCHEMBL5440832 | 0.81 | ALDH1A1 (0.67) | ALDH1A1TSHRTHRBTHRACYP3A4 | |
| SCHEMBL5478851 | 0.80 | TSHR (0.58) | ALDH1A1TSHRTHRBTHRACYP3A4 | |
| SCHEMBL9319827 | 0.77 | TSHR (0.48) | ALDH1A1TSHRTHRBTHRACYP3A4 | |
| SCHEMBL11691799 | 0.77 | ALDH1A1 (0.41) | ALDH1A1TSHRTHRBTHRAHSD17B10 | |
| SCHEMBL680993 | 0.77 | TSHR (0.48) | ALDH1A1TSHRTHRBTHRACYP3A4 | |
| SCHEMBL3645963 | 0.77 | SCN4A (0.48) | ALDH1A1TSHRTHRBTHRACYP3A4 | |
| SCHEMBL4354925 | 0.76 | THRB (0.55) | ALDH1A1TSHRTHRBTHRAHSD17B10 | |
| SCHEMBL94118 | 0.75 | KLK1 (0.45) | ALDH1A1TSHRTHRBTHRACYP3A4 | |
| SCHEMBL11451272 | 0.75 | TSHR (0.39) | ALDH1A1TSHRTHRBTHRACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2115051-B1 | FLAME RETARDANTS FOR USE IN STYRENIC FOAMS | CHEMTURA CORP (US) | 2012-07-11 | — | — | EP | claimed |
| JP-2010520355-A | — | — | 2010-06-10 | — | — | JP | claimed |
| EP-2115051-A2 | FLAME RETARDANTS FOR USE IN STYRENIC FOAMS | CHEMTURA CORPORATION (US) | 2009-11-11 | — | — | EP | claimed |
| EP-1383490-A4 | COMBINATION OF EPOTHILONE ANALOGS AND CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | BRISTOL MYERS SQUIBB CO (US) | 2009-03-18 | — | — | EP | claimed |
| WO-2008121135-A2 | FLAME RETARDANTS FOR USE IN STYRENIC FOAMS | CHEMTURA CORPORATION (US) | 2008-10-09 | — | — | WO | claimed |
| US-20080221230-A1 | Flame retardants for use in styrenic foams | LANXESS SOLUTIONS US INC. | 2008-09-11 | — | — | US | claimed |
| EP-1383490-A1 | COMBINATION OF EPOTHILONE ANALOGS AND CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Bristol-Myers Squibb Company (US) | 2004-01-28 | — | — | EP | claimed |
| WO-2002072085-A1 | COMBINATION OF EPOTHILONE ANALOGS AND CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-09-19 | — | — | WO | claimed |
| EP-2115051-B1 | FLAME RETARDANTS FOR USE IN STYRENIC FOAMS | CHEMTURA CORP (US) | 2012-07-11 | — | — | EP | disclosed |
| US-8084511-B2 | 1,4-bis(2,4,6-tribromophenoxy)-2,3-dibromobutene ( containg both aromatic bromo and internal olefin groups) as flame retardant and extruded polystyrene foam; minimal impact on health and the environment; heat and chemical resistance | CHEMTURA CORPORATION (US) | 2011-12-27 | — | — | US | disclosed |
| US-8084511-B2 | 1,4-bis(2,4,6-tribromophenoxy)-2,3-dibromobutene ( containg both aromatic bromo and internal olefin groups) as flame retardant and extruded polystyrene foam; minimal impact on health and the environment; heat and chemical resistance | CHEMTURA CORPORATION (US) | 2011-12-27 | — | — | US | disclosed |
| US-8084511-B2 | 1,4-bis(2,4,6-tribromophenoxy)-2,3-dibromobutene ( containg both aromatic bromo and internal olefin groups) as flame retardant and extruded polystyrene foam; minimal impact on health and the environment; heat and chemical resistance | CHEMTURA CORPORATION (US) | 2011-12-27 | — | — | US | disclosed |
| EP-2115051-A2 | FLAME RETARDANTS FOR USE IN STYRENIC FOAMS | CHEMTURA CORPORATION (US) | 2009-11-11 | — | — | EP | disclosed |
| WO-2008121135-A2 | FLAME RETARDANTS FOR USE IN STYRENIC FOAMS | CHEMTURA CORPORATION (US) | 2008-10-09 | — | — | WO | disclosed |
| WO-2008121135-A2 | FLAME RETARDANTS FOR USE IN STYRENIC FOAMS | CHEMTURA CORPORATION (US) | 2008-10-09 | — | — | WO | disclosed |
| US-20080221230-A1 | Flame retardants for use in styrenic foams | LANXESS SOLUTIONS US INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080221230-A1 | Flame retardants for use in styrenic foams | LANXESS SOLUTIONS US INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080221230-A1 | Flame retardants for use in styrenic foams | LANXESS SOLUTIONS US INC. | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221230-A1 | Flame retardants for use in styrenic foams | AFF1, AFF2, AFF4 | ALDH1A1 705/4885TSHR 73/4885THRB 616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.